
Dirk M Zajonc

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1060228/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Natural killer T cells recognize diacylglycerol antigens from pathogenic bacteria. Nature Immunology, 2006, 7, 978-986.	14.5	567
2	Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteria. Nature Immunology, 2011, 12, 966-974.	14.5	295
3	Structure and function of a potent agonist for the semi-invariant natural killer T cell receptor. Nature Immunology, 2005, 6, 810-818.	14.5	288
4	T Cell Activation by Lipopeptide Antigens. Science, 2004, 303, 527-531.	12.6	255
5	Crystal structure of CD1a in complex with a sulfatide self antigen at a resolution of 2.15 Ã Nature Immunology, 2003, 4, 808-815.	14.5	218
6	The Identification of the Endogenous Ligands of Natural Killer T Cells Reveals the Presence of Mammalian α-Linked Glycosylceramides. Immunity, 2014, 41, 543-554.	14.3	207
7	Structural basis for CD1d presentation of a sulfatide derived from myelin and its implications for autoimmunity. Journal of Experimental Medicine, 2005, 202, 1517-1526.	8.5	187
8	Anatomy of CD1–lipid antigen complexes. Nature Reviews Immunology, 2005, 5, 387-399.	22.7	165
9	Design of natural killer T cell activators: Structure and function of a microbial glycosphingolipid bound to mouse CD1d. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3972-3977.	7.1	134
10	Type II natural killer T cells use features of both innate-like and conventional T cells to recognize sulfatide self antigens. Nature Immunology, 2012, 13, 851-856.	14.5	123
11	Molecular Mechanism of Lipopeptide Presentation by CD1a. Immunity, 2005, 22, 209-219.	14.3	122
12	Galectin-9 controls the therapeutic activity of 4-1BB–targeting antibodies. Journal of Experimental Medicine, 2014, 211, 1433-1448.	8.5	116
13	Mechanisms for Glycolipid Antigen-Driven Cytokine Polarization by Vα14 <i>i</i> NKT Cells. Journal of Immunology, 2010, 184, 141-153.	0.8	108
14	Galactose-modified iNKT cell agonists stabilized by an induced fit of CD1d prevent tumour metastasis. EMBO Journal, 2011, 30, 2294-2305.	7.8	98
15	Cardiolipin Binds to CD1d and Stimulates CD1d-Restricted γδT Cells in the Normal Murine Repertoire. Journal of Immunology, 2011, 186, 4771-4781.	0.8	97
16	Crystal Structures of Mouse CD1d-iGb3 Complex and its Cognate Vα14ÂT Cell Receptor Suggest a Model for Dual Recognition of Foreign and Self Glycolipids. Journal of Molecular Biology, 2008, 377, 1104-1116.	4.2	94
17	Lipid binding orientation within CD1d affects recognition of <i>Borrelia burgorferi</i> antigens by NKT cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 1535-1540.	7.1	91
18	Toxoplasma gondii peptide ligands open the gate of the HLA class I binding groove. ELife, 2016, 5, .	6.0	88

2

#	Article	IF	CITATIONS
19	Human Cytomegalovirus Glycoprotein UL141 Targets the TRAIL Death Receptors to Thwart Host Innate Antiviral Defenses. Cell Host and Microbe, 2013, 13, 324-335.	11.0	86
20	The Vα14 invariant natural killer T cell TCR forces microbial glycolipids and CD1d into a conserved binding mode. Journal of Experimental Medicine, 2010, 207, 2383-2393.	8.5	78
21	Structural Characterization of Mycobacterial Phosphatidylinositol Mannoside Binding to Mouse CD1d. Journal of Immunology, 2006, 177, 4577-4583.	0.8	72
22	Molecular basis of lipid antigen presentation by <scp>CD</scp> 1d and recognition by natural killer T cells. Immunological Reviews, 2012, 250, 167-179.	6.0	72
23	A ligand-specific blockade of the integrin Mac-1 selectively targets pathologic inflammation while maintaining protective host-defense. Nature Communications, 2018, 9, 525.	12.8	72
24	Using a Combined Computational-Experimental Approach to Predict Antibody-Specific B Cell Epitopes. Structure, 2014, 22, 646-657.	3.3	63
25	Recognition of Lysophosphatidylcholine by Type II NKT Cells and Protection from an Inflammatory Liver Disease. Journal of Immunology, 2014, 193, 4580-4589.	0.8	62
26	Regulatory T Cell–Mediated Suppression of Inflammation Induced by DR3 Signaling Is Dependent on Galectin-9. Journal of Immunology, 2017, 199, 2721-2728.	0.8	60
27	Recognition of Microbial Glycolipids by Natural Killer T Cells. Frontiers in Immunology, 2015, 6, 400.	4.8	58
28	Cutting Edge: Structural Basis for the Recognition of β-Linked Glycolipid Antigens by Invariant NKT Cells. Journal of Immunology, 2011, 187, 2079-2083.	0.8	57
29	Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01. Journal of Biological Chemistry, 2017, 292, 5262-5270.	3.4	57
30	Helicobacter pylori Cholesteryl α-Glucosides Contribute to Its Pathogenicity and Immune Response by Natural Killer T Cells. PLoS ONE, 2013, 8, e78191.	2.5	56
31	CD1 mediated T cell recognition of glycolipids. Current Opinion in Structural Biology, 2007, 17, 521-529.	5.7	52
32	High-Affinity Bent β2-Integrin Molecules in Arresting Neutrophils Face Each Other through Binding to ICAMs In cis. Cell Reports, 2019, 26, 119-130.e5.	6.4	46
33	Unique Interplay between Sugar and Lipid in Determining the Antigenic Potency of Bacterial Antigens for NKT Cells. PLoS Biology, 2011, 9, e1001189.	5.6	43
34	Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling. Journal of Biological Chemistry, 2018, 293, 1317-1329.	3.4	43
35	NKT Cell Ligand Recognition Logic: Molecular Basis for a Synaptic Duet and Transmission of Inflammatory Effectors. Journal of Immunology, 2011, 187, 1081-1089.	0.8	40
36	Potent Neutralization of Vaccinia Virus by Divergent Murine Antibodies Targeting a Common Site of Vulnerability in L1 Protein. Journal of Virology, 2014, 88, 11339-11355.	3.4	40

#	Article	IF	CITATIONS
37	Carbohydrate specificity of the recognition of diverse glycolipids by natural killer T cells. Immunological Reviews, 2009, 230, 188-200.	6.0	38
38	An in silico—in vitro Pipeline Identifying an HLA-A*02:01+ KRAS G12V+ Spliced Epitope Candidate for a Broad Tumor-Immune Response in Cancer Patients. Frontiers in Immunology, 2019, 10, 2572.	4.8	38
39	Glycolipids that Elicit IFN-Î ³ -Biased Responses from Natural Killer T Cells. Chemistry and Biology, 2011, 18, 1620-1630.	6.0	37
40	Enhanced TCR Footprint by a Novel Glycolipid Increases NKT-Dependent Tumor Protection. Journal of Immunology, 2013, 191, 2916-2925.	0.8	37
41	Structure of Human Cytomegalovirus UL141 Binding to TRAIL-R2 Reveals Novel, Non-canonical Death Receptor Interactions. PLoS Pathogens, 2013, 9, e1003224.	4.7	36
42	Control of CD1d-restricted antigen presentation and inflammation by sphingomyelin. Nature Immunology, 2019, 20, 1644-1655.	14.5	35
43	Structural and Biochemical Characterization of the Vaccinia Virus Envelope Protein D8 and Its Recognition by the Antibody LA5. Journal of Virology, 2012, 86, 8050-8058.	3.4	33
44	CD1 assembly and the formation of CD1–antigen complexes. Current Opinion in Immunology, 2005, 17, 88-94.	5.5	32
45	Structural and Functional Characterization of Anti-A33 Antibodies Reveal a Potent Cross-Species Orthopoxviruses Neutralizer. PLoS Pathogens, 2015, 11, e1005148.	4.7	32
46	The crystal structure of avian CD1 reveals a smaller, more primordial antigen-binding pocket compared to mammalian CD1. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17925-17930.	7.1	30
47	Structural Basis for the Recognition of C20:2-αGalCer by the Invariant Natural Killer T Cell Receptor-like Antibody L363*. Journal of Biological Chemistry, 2012, 287, 1269-1278.	3.4	29
48	A Novel Glycolipid Antigen for NKT Cells That Preferentially Induces IFN-Î ³ Production. Journal of Immunology, 2015, 195, 924-933.	0.8	28
49	Crystal structures of the human 4-1BB receptor bound to its ligand 4-1BBL reveal covalent receptor dimerization as a potential signaling amplifier. Journal of Biological Chemistry, 2018, 293, 9958-9969.	3.4	27
50	Structural Basis for Lipid-Antigen Recognition in Avian Immunity. Journal of Immunology, 2010, 184, 2504-2511.	0.8	25
51	Structural and Functional Characterization of a Novel Nonglycosidic Type I NKT Agonist with Immunomodulatory Properties. Journal of Immunology, 2012, 188, 2254-2265.	0.8	24
52	Linear Epitopes in Vaccinia Virus A27 Are Targets of Protective Antibodies Induced by Vaccination against Smallpox. Journal of Virology, 2016, 90, 4334-4345.	3.4	23
53	T-cell activation by lipopeptide antigens. Current Opinion in Immunology, 2005, 17, 222-229.	5.5	22
54	The CD1 family: serving lipid antigens to T cells since the Mesozoic era. Immunogenetics, 2016, 68, 561-576.	2.4	21

#	Article	IF	CITATIONS
55	Autoreactivity to Sulfatide by Human Invariant NKT Cells. Journal of Immunology, 2017, 199, 97-106.	0.8	19
56	Structure–function characterization of three human antibodies targeting the vaccinia virus adhesion molecule D8. Journal of Biological Chemistry, 2018, 293, 390-401.	3.4	19
57	Crystal structure of the m4-1BB/4-1BBL complex reveals an unusual dimeric ligand that undergoes structural changes upon 4-1BB receptor binding. Journal of Biological Chemistry, 2019, 294, 1831-1845.	3.4	18
58	Restriction of Human Cytomegalovirus Infection by Galectin-9. Journal of Virology, 2019, 93, .	3.4	18
59	Murine Anti-vaccinia Virus D8 Antibodies Target Different Epitopes and Differ in Their Ability to Block D8 Binding to CS-E. PLoS Pathogens, 2014, 10, e1004495.	4.7	17
60	The bovine CD1D gene has an unusual gene structure and is expressed but cannot present α-galactosylceramide with a C26 fatty acid. International Immunology, 2013, 25, 91-98.	4.0	16
61	Crystal Structure of Bovine CD1b3 with Endogenously Bound Ligands. Journal of Immunology, 2010, 185, 376-386.	0.8	15
62	Lipid and Carbohydrate Modifications of α-Galactosylceramide Differently Influence Mouse and Human Type I Natural Killer T Cell Activation. Journal of Biological Chemistry, 2015, 290, 17206-17217.	3.4	15
63	Structure of human cytomegalovirus UL144, an HVEM orthologue, bound to the B and T cell lymphocyte attenuator. Journal of Biological Chemistry, 2019, 294, 10519-10529.	3.4	15
64	Crystal Structures of Bovine CD1d Reveal Altered αGalCer Presentation and a Restricted A' Pocket Unable to Bind Long-Chain Glycolipids. PLoS ONE, 2012, 7, e47989.	2.5	14
65	Synthesis of C-5″ and C-6″-modified α-GalCer analogues as iNKT-cell agonists. Bioorganic and Medicinal Chemistry, 2015, 23, 3175-3182.	3.0	14
66	4"â€Oâ€Alkylated αâ€Galactosylceramide Analogues as <i>i</i> NKTâ€Cell Antigens: Synthetic, Biological, an Structural Studies. ChemMedChem, 2019, 14, 147-168.	d _{3.2}	14
67	CD1, MR1, NKT, and MAIT: evolution and origins of non-peptidic antigen recognition by T lymphocytes. Immunogenetics, 2016, 68, 489-490.	2.4	13
68	Structure of an α-Helical Peptide and Lipopeptide Bound to the Nonclassical Major Histocompatibility Complex (MHC) Class I Molecule CD1d*. Journal of Biological Chemistry, 2016, 291, 10677-10683.	3.4	10
69	Galactosylsphingamides: new α-GalCer analogues to probe the F'-pocket of CD1d. Scientific Reports, 2017, 7, 4276.	3.3	10
70	Selfâ€glycerophospholipids activate murine phospholipidâ€reactive TÂcells and inhibit iNKTÂcell activation by competing with ligands for CD1d loading. European Journal of Immunology, 2019, 49, 242-254.	2.9	7
71	Unconventional Peptide Presentation by Classical MHC Class I and Implications for T and NK Cell Activation. International Journal of Molecular Sciences, 2020, 21, 7561.	4.1	6
72	Crystal structure of Qa-1a with bound Qa-1 determinant modifier peptide. PLoS ONE, 2017, 12, e0182296.	2.5	6

#	Article	IF	CITATIONS
73	The structure of cytomegalovirus immune modulator UL141 highlights structural Ig-fold versatility for receptor binding. Acta Crystallographica Section D: Biological Crystallography, 2014, 70, 851-862.	2.5	5
74	Structure-Function Implications of the Ability of Monoclonal Antibodies Against α-Galactosylceramide-CD1d Complex to Recognize β-Mannosylceramide Presentation by CD1d. Frontiers in Immunology, 2019, 10, 2355.	4.8	5
75	Characterization of murine antibody responses to vaccinia virus envelope protein A14 reveals an immunodominant antigen lacking of effective neutralization targets. Virology, 2018, 518, 284-292.	2.4	2
76	Evolution of differential 4â€1BB signaling in Human and Murine immune system. FASEB Journal, 2019, 33, 461.3.	0.5	2
77	A γδTâ€cell glimpse of glycolipids. Immunology and Cell Biology, 2014, 92, 99-100.	2.3	1
78	CD1c caves in on lipids. Nature Immunology, 2018, 19, 322-324.	14.5	1
79	A molecular switch in mouse CD1d modulates natural killer T cell activation by α-galactosylsphingamides. Journal of Biological Chemistry, 2019, 294, 14345-14356.	3.4	1
80	Catching a complex for optimal signaling. Journal of Biological Chemistry, 2019, 294, 13887-13888.	3.4	1
81	Galactose modified iNKT cell agonists stabilised by a novel structural modification of CD1d lead to marked Th1 polarisation in vivo. Annals of the Rheumatic Diseases, 2011, 70, A53-A53.	0.9	0
82	Structural basis of NKT cell inhibition using the T-cell receptor-blocking anti-CD1d antibody 1B1. Journal of Biological Chemistry, 2019, 294, 12947-12956.	3.4	0
83	Molecular Characterization of the Native (Non-Linked) CD160–HVEM Protein Complex Revealed by Initial Crystallographic Analysis, Crystals, 2021, 11, 820.	2.2	0